단계 미표기모집 중단 (진행 중)
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients
연구 개요
This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US electronic health record (EHR)-based databases.
- 스폰서
- 리드: 리제네론
- 적응증
- Advanced Non-small Cell Lung Cancer
- 중재
- REGN2810, Platinum-doublet chemotherapy
- 목표 등록
- 1,000명
- 시작일
- 2024-02-21
- 완료(예정)
- 2027-06-23
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.